"Sample integrity, and the ease and economy of transporting collected samples are key components to testing during outbreaks," said Gerald Fischer, MD, Longhorn Vaccines & Diagnostics' Chief Executive Officer. "An infectious disease physician and a molecular biologist designed The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ to generate rapid, high quality PCR results, in as little as two hours while improving safety, and reducing laboratory preparation time."
2009 H1N1 is a new influenza virus that was detected in the United States in April 2009. As such, children and younger adults are less likely than older people to have immunity to this virus, and illness may be more severe and widespread as a result (1). In June 2009, the World Health Organization (WHO) announced that the spread of the novel 2009 H1N1 virus had reached pandemic phase 6, the highest level of pandemic alert designated by the organization (2).
"Influenza-like-illness puts a significant strain on Emergency Departments during the standard Influenza season. The atypical epidemiology of H1N1-09 has magnified the impact on healthcare systems around the world. The principal morbidity and mortality of H1N1-09 was in young, previously healthy patients who accessed the system in large numbers. We were quite fortunate this time around that it came early, during relatively mild weather. Having access to reliabl
|SOURCE Longhorn Vaccines & Diagnostics|
Copyright©2010 PR Newswire.
All rights reserved